DK2310043T4 - Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere - Google Patents

Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere Download PDF

Info

Publication number
DK2310043T4
DK2310043T4 DK09777111.7T DK09777111T DK2310043T4 DK 2310043 T4 DK2310043 T4 DK 2310043T4 DK 09777111 T DK09777111 T DK 09777111T DK 2310043 T4 DK2310043 T4 DK 2310043T4
Authority
DK
Denmark
Prior art keywords
treatment
factor
von willebrand
platelet inhibitors
defect induced
Prior art date
Application number
DK09777111.7T
Other languages
Danish (da)
English (en)
Other versions
DK2310043T3 (da
Inventor
Gerhard Dickneite
Ingo Pragst
Henrique Lessa
Thorsten Haas
Stefan Zeitler
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2310043(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2310043T3 publication Critical patent/DK2310043T3/da
Publication of DK2310043T4 publication Critical patent/DK2310043T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09777111.7T 2008-07-10 2009-07-10 Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere DK2310043T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (2)

Publication Number Publication Date
DK2310043T3 DK2310043T3 (da) 2013-01-07
DK2310043T4 true DK2310043T4 (da) 2022-06-20

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09777111.7T DK2310043T4 (da) 2008-07-10 2009-07-10 Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere

Country Status (13)

Country Link
US (2) US8603979B2 (enExample)
EP (1) EP2310043B2 (enExample)
JP (1) JP5653916B2 (enExample)
KR (1) KR20110043654A (enExample)
CN (1) CN102088999A (enExample)
AU (1) AU2009268289B2 (enExample)
CA (1) CA2730290C (enExample)
DE (1) DE102008032361A1 (enExample)
DK (1) DK2310043T4 (enExample)
ES (1) ES2395855T5 (enExample)
PL (1) PL2310043T5 (enExample)
RU (1) RU2563236C2 (enExample)
WO (1) WO2010003687A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
ATE430578T1 (de) 1999-12-24 2009-05-15 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
EP2310043B2 (en) 2022-05-18
CN102088999A (zh) 2011-06-08
JP5653916B2 (ja) 2015-01-14
US9095564B2 (en) 2015-08-04
EP2310043A1 (en) 2011-04-20
ES2395855T5 (es) 2022-09-06
KR20110043654A (ko) 2011-04-27
WO2010003687A1 (en) 2010-01-14
EP2310043B1 (en) 2012-09-19
PL2310043T5 (pl) 2024-02-05
PL2310043T3 (pl) 2013-02-28
AU2009268289B2 (en) 2014-11-06
DE102008032361A1 (de) 2010-01-21
CA2730290C (en) 2017-02-07
US8603979B2 (en) 2013-12-10
AU2009268289A1 (en) 2010-01-14
ES2395855T3 (es) 2013-02-15
US20110112023A1 (en) 2011-05-12
DK2310043T3 (da) 2013-01-07
RU2011104705A (ru) 2012-08-20
CA2730290A1 (en) 2010-01-14
US20140128325A1 (en) 2014-05-08
JP2011527301A (ja) 2011-10-27
RU2563236C2 (ru) 2015-09-20

Similar Documents

Publication Publication Date Title
DK2310043T3 (da) Von Willebrand faktor eller faktor VII samt von Willebrand faktor til behandling af koagulationsdefekt induceret af trombocythæmmere
DE602007006451D1 (de) Verfahren zur behandlung von bohrlöchern mit wiederverwertbaren flüssigkeiten
EP3299380C0 (en) POLYPEPTIDE PURIFICATION PROCESS
EP4091585C0 (en) DEVICE FOR TREATMENT OF PATHOLOGICAL GASTRO-SOPHAGEAL REFLUX
ATE523949T1 (de) Verfahren zur regelung von wechselrichtern
EP2114460A4 (en) METHODS AND COMPOSITIONS FOR THE DISRUPTION OF BIOLOGICAL FILMS
EP1973497A4 (en) PROCESS FOR FAST REPAIR OF BODY LINES
EP2349310A4 (en) POLYPEPTIDE FOR THE MANAGEMENT OR PREVENTION OF ADHESIONS
DK2245069T3 (da) Humaniserede antistoffer specifikke for von Willebrand faktor
EP2432599A4 (en) HARD DISK DRIVE DESTRUCTION SYSTEM
EP4144367C0 (en) METHODS FOR MANIPULATING CD47-MEDICATED PHAGOCYTOSIS
DK2882450T3 (da) Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
EP2795681A4 (en) CIRCUITS AND METHODS FOR LIMITING OPEN CIRCUIT VOLTAGE OF PHOTOVOLTAIC CHAINS
DE602008000298D1 (de) Verfahren zur Herstellung von Polyesternanokompositen
DE602007010303D1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
DE602006018197D1 (de) Ntsprechendes verfahren zum verfolgen der präsenz
BRPI0907146A2 (pt) recipiente plástico de uma peça e método de fazer o mesmo
AT505105A3 (de) Verfahren zur beurteilung der fahrbarkeit von fahrzeugen
EP2579936A4 (en) INTRAGASTRIC DEVICE FOR TREATING OBESITY
DE602007005067D1 (de) Anlage zur Lagerung von Artikeln und Steuerverfahren dafür
DE602008005676D1 (de) Nicht-fotorealistische Darstellung von Konturen
DE602008005066D1 (de) Nicht-fotorealistische Darstellung von Konturen
DE602008004594D1 (de) Nicht-fotorealistische Darstellung von Konturen
EP2403503A4 (en) METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES
EP2257516A4 (en) METHODS FOR PREPARING CYCLODODECATRIENE AND METHODS FOR PREPARING LAUROLACTONE